Slide 1: Third Quarter 2022 Earnings and Acquisition of Fulgent Pharma
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Announces Third Quarter 2022 Earnings and Acquisition of Fulgent Pharma November 7, 2022 Exhibit 99.4
Slide 2: Disclaimer: Forward-Looking Statements and Market Data
Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “Company”) about future events based on current vie
Slide 3: Ming Hsieh, Chairman, CEO, Founder
Ming Hsieh Chairman, CEO, Founder
Slide 4: Transaction Overview
Transaction Overview Genes & Panels Tumor Profiling Known Mutation Newborn Genetics Hereditary Cancer Carrier Screens Genomic Testing Sequencing Service Infectious Disease Spatial Biology Fulgent Genetics acquired all outstanding capital stock of Fulgent Pharma at an enterprise value of $100 million
Slide 5: Fulgent Genetics + Fulgent Pharma History
Fulgent Pharma and Fulgent Genetics combined entity positioned to unlock significant long-term upside for both the therapeutics and diagnostic businesses while effectively managing risk Fulgent Genetics + Fulgent Pharma History 2011 Fulgent Therapeutics founded as combined pharma and genetics compan
Slide 6: Strategic Vision – A One-stop Solution for Cancer Care
Strategic Vision – A One-stop Solution for Cancer Care VISION Leading Genetic Testing Company Offering Tech-Enabled Diagnostic Solutions Therapeutic and Diagnostic Entity Providing Comprehensive Solutions Across the Cancer Care Continuum Vertically integrated “one-stop” solution across the healthcar
Slide 7: Long-Term Vision: Fulgent Continuum of Care
Long-Term Vision: Fulgent Continuum of Care Diagnosis Well-funded by diagnostics to advance H&N therapy trials and commercialization process Genomics data accelerates pipeline therapeutics development, e.g. spatial biology for tumor micro-environment profiling Long-term opportunity to leverage data
Slide 8: Potential Market Opportunity
Potential Market Opportunity Pancreatic $1.1B in 2021 $1.5B by 2035 NSCLC $121M in 2021 $140M by 2035 Breast $498M in 2021 $521M by 2035 H&N $2.2B in 20211 $2.9B by 20351 Note: U.S. opportunity shown Sources: Evaluate Pharma and Wall Street research estimates H&N market opportunity for both 2nd line
Slide 9: Dr. Ray Yin, Ph.D., President of Fulgent Pharma
Dr. Ray Yin, Ph.D. Co-Founder of Fulgent Therapeutics President of Fulgent Pharma Founder & CEO, ANP Technologies, Inc. Former Team Leader of Nanobiotechnology for Chem/Bio Defense, U.S. Army Research Laboratory Holder of 46 drug delivery/detection patents
Slide 10: Nano-Drug Delivery Platform Overview
Nano-Drug Delivery Platform Overview Many drug candidates failed during preclinical and clinical development and testing due to poor water solubility Nanoencapsulation produces amorphous drug candidates with improved solubility and potentially enhanced absorption, drug PK profiles, safety and effica
Slide 11: FID-007 Program Overview
FID-007 Program Overview FID-007 Phase I Preliminary Highlights (as of 6/10/22): H&N Cancer 100% Disease Control Rate (DCR1) and 33% Overall Response Rate (ORR) were observed in 6 heavily treated H&N patients Ampullary/Pancreatic 75% DCR and 50% ORR were seen in 4 heavily treated ampullary and pancr
Slide 12: FID-007 and Other Candidates Using our Nano Delivery Platform
FID-007 and Other Candidates Using our Nano Delivery Platform FID-007 Drug Candidates Pre-Clinical Wholly-owned drug candidate focused on Head & Neck (H&N), Pancreatic, Lung, and Breast Cancer Seeking initial therapeutic indication for 2nd or 3rd line treatment of H&N cancer Exploring potential ampu
Slide 13: Preclinical Pipeline
Preclinical Pipeline Robust Pipeline Focused on Unmet Needs in Oncology Genomic Database Fuels Development and Addresses Issues of Drug Resistance Drug Candidates Target Indication FID-021 Undisclosed Multiple Cancer FID-023 Undisclosed Leukemia FID-025 Undisclosed Brain Cancer 505(b)(2) Approach NC
Slide 14: Ming Hsieh, Chairman, CEO, Founder
Ming Hsieh Chairman, CEO, Founder
Slide 15: Key Takeaways
Key Takeaways Transaction reinforces Founder vision and potentially transforms the existing business into a new paradigm, generating a creative and sustainable business model in precision medicine for years to come “One-stop” shop verticalized across the healthcare chain and Fulgent Genetics’ increa
Slide 16: Third quarter 2022 financial results
Third quarter 2022 financial results
Slide 17: Brandon Perthuis, Chief Commercial Officer
Brandon Perthuis Chief Commercial Officer
Slide 18: Paul Kim, Chief Financial Officer
Paul Kim Chief Financial Officer
Slide 19: Q&A
Q&A
Slide 20: Founded in 2011 | Located in Los Angeles, CA |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT